Intravenous esketamine in pediatric Rett syndrome: An open-label, early phase 1 pilot study

Intravenous esketamine in pediatric Rett syndrome: An open-label, early phase 1 pilot study

Rett syndrome (RTT) is a severe neurodevelopmental disorder. N-Methyl-d-aspartate receptor (NMDAR) antagonism has shown therapeutic potential in preclinical RTT models. We performed a pilot study to explore whether intravenous esketamine, an NMDAR antagonist, alleviates the symptoms of pediatric RTT...

Full description

Saved in:
Bibliographic Details
Main Authors: Huiping Li, Shu Liu, Caimei Lin, Yuchao Wu, Xiuping Wu, Yukun Huang, Yajun Wu, Xiubin Tong, Xiu Xu
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
Rett syndrome
esketamine
N-methyl-d-aspartate receptor antagonist
efficiency
safety
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050125000087
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items